GlobeNewsWire
06 Jul 2026, 21:25 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
GRAIL's NHS-Galleri Trial failed to achieve its primary endpoint of reducing late-stage cancer diagnoses. — The failure of a core clinical trial for a cancer detection company directly undermines its primary value proposition and product viability.
-0.90GRAIL is facing a securities class action lawsuit alleging it misled investors regarding the NHS-Galleri trial's design and likelihood of success. — Legal challenges and allegations of executive fraud create significant regulatory risk and potential future financial liabilities.
-0.50The company experienced a market capitalization loss of over $2.2 billion, with shares dropping over 50% following the trial results. — This confirms a massive loss of investor confidence and a severe correction in the company's valuation.
-0.30Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company suffered a $2.2 billion market cap loss, a trial failure, and is facing a securities class action lawsuit.
Mentioned as having a plunging stock price due to allegedly misleading financial statements.
Mentioned as having a plunging stock price due to allegedly misleading financial statements.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
